Fig. 4From: Surrogacy of one-year survival for overall survival in advanced hepatocellular carcinomaSubgroup analyses in trials relevant to immune checkpoint inhibitors (ICIs). The correlation was strong between progression-free survival (PFS) and overall survival (OS) (A, B). One-year milestone survival did not strongly correlate with OS in ICI trials (C, D)Back to article page